Tesetaxel: Preliminary Phase I data

Preliminary data from 9 evaluable patients in an ongoing Phase I trial showed that 18-24 mg/m 2 oral tesetaxel resulted in 3 objective responses and 1 case of Grade 4 neutropenia. Previous Phase II tr...